Nortopixantrone
Alternative Names: BBR 3438Latest Information Update: 18 Nov 2002
At a glance
- Originator Novuspharma; University of Vermont
- Developer Novuspharma
- Class Anthraquinones; Antineoplastics; Pyrazolones; Small molecules
- Mechanism of Action DNA inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Gastric cancer; Ovarian cancer; Prostate cancer
Most Recent Events
- 18 Nov 2002 Discontinued - Phase-II for Gastric cancer in Europe (IV)
- 18 Nov 2002 Discontinued - Phase-II for Gastric cancer in Germany (unspecified route)
- 18 Nov 2002 Discontinued - Phase-II for Ovarian cancer in Europe (IV)